Evaluation of the effects of cabergoline (Dostinex) on women with symptomatic myomatous uterus: a randomized trial

Abstract

ObjectiveMyoma is one of the most common benign tumors of uterus and one of the most common causes of vaginal bleeding in women. The purpose of the present study is to evaluate the effect of dopamine receptor agonist cabergoline on the size of myoma and the amount of bleeding in the women with myoma of the uterus. Study designThe study was performed as a single blind randomized clinical trial on the women with symptomatic myoma. The women were randomly assigned in 2 groups. In the case group, 0.5mg cabergoline was prescribed weekly for three months, and in the control group, nothing was prescribed and the women only had close observation for symptoms.The reduction in symptoms including pelvic pain and duration and amount of uterine bleeding, and the size of myoma, were compared between the 2 groups. Results51 women finished the study (26 women in the case group and 25 women in the control group).There was no significant difference between the 2 groups according to age, gravidity, parity, history of abortion, having living children, pretreatment hemoglobin, pain and amount of uterine bleeding, uterine size, and the size of myoma.After treatment, hemoglobin levels had dropped in the control group but not in the case group (p=0.004). On the other hand, pain had also decreased significantly in the case group in comparison with the control group (p=0.001).Also, the amount of menstrual bleeding (p=0.004), uterine size (p=0.001) and the size of the largest myoma (p=0.013) showed significant reduction in the case group. ConclusionCabergoline can decrease the amount of bleeding and pain in the cases of myomatous uterus and can be used for the symptomatic women who want to preserve uterus for a certain period of time.